Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Podobne knjige/članki

• EGFR activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity
  od: Pfäffle, Heike N., et al.
  Izdano: (2013)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  od: Khandekar, Melin J., et al.
  Izdano: (2018)
• Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
  od: Piotrowska, Zofia, et al.
  Izdano: (2015)
• Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period
  od: McClatchy, David M., et al.
  Izdano: (2020)
• The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
  od: Niederst, Matthew J., et al.
  Izdano: (2015)